Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Sanofi-Aventis |
---|---|
Information provided by: | Sanofi-Aventis |
ClinicalTrials.gov Identifier: | NCT00549133 |
To show that Irbesartan improves endothelial dysfunction and the procoagulant state which are thought to be the possible mechanisms, inducing a generalized vasculopathy associated with microalbuminuria and vascular events in type II diabetic hypertensive patients
Condition | Intervention | Phase |
---|---|---|
Hypertension Diabetes Mellitus Type 2 |
Drug: Irbesartan |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | Irbesartan Effects on Endothelial Dysfunction in Hypertensive Type II Diabetic Patients Comparing Atenolol |
Enrollment: | 44 |
Study Start Date: | October 2003 |
Study Completion Date: | April 2005 |
Ages Eligible for Study: | 40 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Study ID Numbers: | L_9130 |
Study First Received: | October 24, 2007 |
Last Updated: | October 24, 2007 |
ClinicalTrials.gov Identifier: | NCT00549133 |
Health Authority: | Turkey: Ministry of Health |
Microalbuminaria in hypertensive patients with type II diabetes mellitus |
Metabolic Diseases Diabetes Mellitus, Type 2 Irbesartan Vascular Diseases Diabetes Mellitus Endocrine System Diseases |
Endocrinopathy Angiotensin II Atenolol Metabolic disorder Glucose Metabolism Disorders Hypertension |
Angiotensin II Type 1 Receptor Blockers Molecular Mechanisms of Pharmacological Action Therapeutic Uses Cardiovascular Diseases |
Cardiovascular Agents Antihypertensive Agents Pharmacologic Actions |